Skip to main content
Clinical Trials/EUCTR2004-002798-21-HU
EUCTR2004-002798-21-HU
Active, Not Recruiting
N/A

A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella

F.Hoffmann-La Roche Ltd0 sites300 target enrollmentMay 18, 2005

Overview

Phase
N/A
Intervention
Not specified
Conditions
Community-acquired pneumonia
Sponsor
F.Hoffmann-La Roche Ltd
Enrollment
300
Status
Active, Not Recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 18, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients will qualify to participate in this study if they meet all of the following:
  • 1\. Are male or female patients greater than or equal to 18 years of age that require hospitalization with community\-acquired pneumonia or develops pneumonia within 48 hours of hospitalization for another condition.
  • 2\. Have fever defined as body temperature \> 38\.0°C (100\.4°F) taken orally; or \> 38\.5°C (101\.2°F) tympanically; OR have hypothermia, defined as rectal or core body
  • temperature \< 36°C (96\.8°F).
  • 3\. Have a new or increased cough productive of purulent sputum for culture and
  • susceptibility testing.
  • 4\. Have either pleuritic chest pain, dyspnea, or tachypnea.
  • 5\. Have auscultatory findings consistent with pneumonic consolidation or pneumopathic process consistent with the diagnosis of pneumonia.
  • 6\. Have chest x\-ray confirmation of infiltrate or lobar consolidation.
  • 7\. Have obtained respiratory secretion specimen and two blood cultures prior to administration of IV study drug or non\-study short acting third generation cephalosporine. (Respiratory

Exclusion Criteria

  • Patients will be excluded if they meet any of the following:
  • 1\. Have a Pneumonia Severity Index \<71 or \>130\.
  • 2\. Have presented with sustained shock, defined as systolic blood pressure \< 90 mm Hg for \> 2 hours despite adequate fluid resuscitation, with evidence of hypoperfusion or need for sympathomimetic agents to maintain blood pressure.
  • 3\. In the opinion of the investigator, history, physical examination and chest X\-ray
  • findings are most consistent with an atypical pneumonia.
  • 4\. Require endotracheal intubation and ventilation, or in the opinion of the investigator, are expected to require it.
  • 5\. Are likely to be discharged in less than 3 days.
  • 6\. Developed pneumonia after more than 48 hours of admission to hospital.
  • 7\. Have been a resident in a nursing home or extended care facility within 60 days prior to randomization.
  • 8\. Require hemodialysis, peritoneal dialysis, plasmapheresis or hemoperfusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella
EUCTR2004-002798-21-SKF.Hoffmann-La Roche Ltd300
Active, Not Recruiting
N/A
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella - CAPTURECommunity-acquired pneumonia
EUCTR2004-002798-21-LVF.Hoffmann-La Roche Ltd300
Active, Not Recruiting
N/A
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella
EUCTR2004-002798-21-LTF.Hoffmann-La Roche Ltd300
Active, Not Recruiting
Phase 1
The effect of SJX-653 on Menopausal Hot FlushesTreatment of moderate to severe vasomotor symptoms (VMS) associatedwith menopause.MedDRA version: 21.1Level: LLTClassification code 10027311Term: Menopause flushingSystem Organ Class: 100000004872Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
EUCTR2019-002281-12-GBSojournix, Inc.66
Unknown
Phase 2
A Clinical Study of NTx-265: human chorionic gonadotropin (hCG) and epoetin alfa (EPO) in acute ischemic stroke patients
CTRI/2008/091/000262Stem Cell Therapeutics Corp